Abstract
Given the high prevalence of migraine treatment failure and resistance to existing drugs and side effects of drugs, finding alternative therapies for refractory patients or chronic migraine is essential. Fifty four patients with migraine headaches were stochastic classified to the 2 groups: placebo and memantine. In first one, memantine is managed at a dose of 20 mg in a day, that enhanced 4 weeks to this dose, and in second group placebo was given. The severity, duration, incapacity, and frequency of migraine headache attacks were recorded at the starting of the research, and the end of first, second, third and fourth months of the study. The mean of VAS score did not have a significant difference at the beginning of the study and at the end of the first month, however here was a significant decrease in the memantine group, during the end of second, third and fourth. After 4 months of behaving, MIDAS score were 22.44±10.62 in the memantine group, when in the placebo group, this was 14.47±1.79 (p <0.0001). The outcomes shows the role of memantine on the treatment and prevention of chronic migraine headaches. In addition, the migraine headaches incidence is mainly decreased in the memantine group in comparison to placebo at the end of the research.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call